Additionally, heterozygous CDKN2A/B deletions in gliomas, detected in 17% of primary IDH-mut gliomas, hold prognostic significance akin to homozygous deletions, highlighting their relevance in glioma progression [18]. This evidence concerns the gene CDKN2A and central nervous system cancer.